Importance Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for
patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal …

Background Postoperative adjuvant cisplatin-based chemotherapy had been the standard
care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer …

PURPOSE To provide evidence-based recommendations to practicing clinicians on
radiographic imaging and biomarker surveillance strategies after definitive curative-intent …

Background Cisplatin-based chemotherapy was previously considered as the standard
adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung …

Aim This analysis evaluated the efficacy and safety of nivolumab, an immune checkpoint
inhibitor, in elderly patients with stage IIIB or IV squamous non–small-cell lung cancer …

Introduction Adjuvant gefitinib therapy prolonged disease-free survival in patients with
resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG …

Objective: To evaluate whether an association exists between the intensity of surveillance
following surgical resection for non–small cell lung cancer (NSCLC) and survival …

Background Prior studies in the civilian population have reported racial disparities in lung
cancer outcomes following surgical treatment, including inferior quality of care and worse …

Background It is evident that comorbidity exacerbate the complexity of the management of
lung cancer, however, limited research has been conducted to investigate the impact of …

Introduction Cancer incidence, comorbidity, and polypharmacy increase with age, but the
interplay between these factors on receipt of systemic therapy (ST) in advanced cancer has …